// dose-graded effects
Ipamorelin Benefits Reported in Research
The skeletal and body-composition findings, gathered in one place, with every figure tied to the study that measured it.
The gist
The ipamorelin benefits reported in research are mostly skeletal and mostly from rats. The headline is a dose-response: more ipamorelin meant faster bone growth, in steady steps. Over longer exposure, bones in rats carried more total mineral and grew larger. When a steroid was working against bone, ipamorelin partly pushed back. And underneath all of it sits the molecule's signature trick — it raises growth hormone without raising the stress hormone cortisol, which is what separates it from older peptides in its family. These are animal findings measured carefully, plus a small amount of human pharmacology; none of it is a proven human benefit, and the community-reported upsides like better sleep live separately on the effects page because they are anecdotal.
Dose-graded bone growth: the cleanest benefit on record
The most quantitatively satisfying ipamorelin benefit is a stepwise bone-growth response. Subcutaneous ipamorelin at 18, 90 and 450 microg/day (split three times daily for 15 days) lifted longitudinal bone growth rate in adult female rats from 42 microm/day on vehicle to 44, 50 and 52 microm/day — each dose a clear step up [2]. The accompanying detail matters: total IGF-1 (the liver's growth-relay hormone) and bone-turnover markers did not measurably move, so the skeletal gain tracked the dose without a matching rise in circulating growth factor — a partly local, pulse-driven effect [2]. It is preclinical and short (15 days), but it is the dose-response that anchors this site's bone-skeletal reading.
More bone mineral, bigger bones
Longer exposure builds on that. Continuous ipamorelin 0.5 mg/kg/day by osmotic minipump for 12 weeks raised total tibial and vertebral bone mineral content on DXA in young female rats, while cortical volumetric bone mineral density was unchanged [3]. The honest interpretation is dimensional: the bones got bigger and held more total mineral, but the cortex did not get denser — growth by expansion rather than densification [3]. It is a real, measured skeletal benefit, and it is also a precise one — worth stating exactly, because "bigger bones" and "denser bones" are not the same claim.
Holding bone against a steroid
Glucocorticoids erode bone formation, and ipamorelin partly counters that. In 8-month-old female rats, ipamorelin 100 microg/kg three times daily for 3 months (alongside methylprednisolone) raised the periosteal bone formation rate roughly four-fold versus the steroid alone and increased maximum tetanic muscle tension [4]. A companion study confirmed the growth-hormone response to ipamorelin was not blunted by methylprednisolone, and that the combination raised IGF-1 and improved body-weight recovery versus steroid alone [5]. The benefit here is resilience — ipamorelin's pulse keeps working under a glucocorticoid load that would otherwise suppress bone formation.
The benefit that underlies all the others: selectivity
The mechanistic benefit threading through every result is clean selectivity. Ipamorelin releases growth hormone potently — swine ED50 2.3 nmol/kg, comparable to GHRP-6 — but does not raise ACTH or cortisol above the GHRH-induced level even at doses more than 200-fold above its growth-hormone ED50 [1]. That means the skeletal and body-composition effects come without the adrenal stimulation and prolactin rise that older growth-hormone-releasing peptides carry [1]. It is the reason ipamorelin is described as the first selective growth-hormone secretagogue, and the reason its benefit profile reads cleaner than its predecessors'.
The muscle and recovery signal — preclinical, not proven
A second cluster of reported ipamorelin benefits centers on muscle and recovery, and here the evidence is thinner and animal-bound. In the steroid-rescue rat study, ipamorelin did not just protect bone — it raised maximum tetanic muscle tension, the peak force a muscle can generate, versus the steroid alone [4]. A 2026 orthopaedic review extended this to the combination: CJC-1295 plus ipamorelin improved maximum tetanic tension in a glucocorticoid-induced muscle-loss model in mice, though the authors stressed the evidence is limited to animal studies [16]. There is no controlled human trial showing ipamorelin builds muscle, so this sits as a preclinical signal — real in rodents, unproven in people. It is worth keeping separate from the community-reported recovery accounts, which are anecdotal rather than measured.
The metabolic and body-composition picture
Beyond bone and muscle, ipamorelin's reported benefits brush against metabolism and body composition — and the data here is mixed enough to demand care. In mice, ipamorelin stimulated adiposity and raised leptin independently of growth hormone after two weeks of dosing [11], meaning part of its body-composition effect runs through direct ghrelin-receptor signaling rather than the growth-hormone axis. In a 2024 ferret model, ipamorelin (1-3 mg/kg) blunted chemotherapy-induced body-weight loss by about 24% — a peripheral anti-cachexia effect, useful context for the weight-preservation angle, but not the same as fat loss [8]. The community framing of ipamorelin as a lean-out compound therefore outruns the controlled evidence: the measured signals point to weight preservation and growth-hormone-independent fat-tissue effects in animals, not a demonstrated human fat-loss benefit.
Where the benefits stop, stated plainly
An honest benefits page has to mark its own edges. Every skeletal and muscle finding above is preclinical — rats and mice, not human outcomes — and the only human efficacy test ipamorelin ever faced, a Phase 2 trial for slowed bowel recovery after surgery, missed its primary endpoint [7]. The human pharmacology that does exist is limited to one small dose-ranging study [6]. So the benefits reported in research are best read as a strong, reproducible animal signal — particularly on the skeletal side — paired with an honest absence of proven human benefit. For the community-reported, non-clinical upsides — sleep, recovery, body composition over time — see the Ipamorelin effects page, where they are clearly labeled anecdotal, not clinical evidence.